Oxygen Biotherapeutics, Inc. (OBI) has posted the protocol of its Phase III trial for levosimendan on ClinicalTrials.gov. The protocol, “Levosimendan in Patients with Left Ventricular Systolic Dysfunction Undergoing Heart Surgery on Cardiopulmonary Bypass,” is available here. OBI previously selected Duke University’s Duke Clinical Research Institute (DCRI) to conduct the Phase III trial of the levosimendan. The trial will be conducted in approximately 50 major cardiac surgery centers in North A...